GI indications¹

OPDIVO in combination with fluoropyrimidine and platinum based combination chemotherapy is indicated for the first line treatment of adult patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5.

OPDIVO as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

OPDIVO in combination with YERVOY is indicated for the first line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD L1 expression ≥ 1 %.

OPDIVO in combination with fluoropyrimidine and platinum based combination chemotherapy is indicated for the first line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1 %.

OPDIVO as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum based combination chemotherapy.

OPDIVO in combination with YERVOY is indicated for the first-line treatment of adult patients with unresectable or metastatic mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC).

OPDIVO in combination with YERVOY is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability high colorectal cancer after prior fluoropyrimidine based combination chemotherapy

OPDIVO in combination with YERVOY is indicated for the first line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

Reference: 

1. Opdualag SmPC